country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-180172

Copy Link Print Information

TRK-IN-33

TRK-IN-33 is a TRK inhibitor. TRK-IN-33 exhibits excellent TRKA^G667C degradation (DC₅₀ = 24.69 nM; D_max > 90%), while sparing the wild-type protein in virto. TRK-IN-33 shows antiproliferative activities against Ba/F3-LMNA-NTRK1^G667C cells with an IC₅₀ value of 2.48 nM. TRK-IN-33 effectively inhibits tumor growth and enhances apoptosis in tumor tissues with no apparent toxicity in vivio. TRK-IN-33 can be used for NTRK fusion−positive cancers research.

For research use only. We do not sell to patients.

Formula: C₂₂H₂₂ClFN₆O₃
Molecular Weight:472.90

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

TRK-IN-33 Chemical Structure

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

TrkA

All Trk Receptor Isoforms :

In Vitro

TRK-IN-33 (compound 20) (0.1-10 μM) exhibits excellent degradation efficiency against TRKA^G667C resistant mutation (degradation = -1.16% at 0.1 μM, degradation = 69.30% at 1 μM, degradation = 68.75% at 10 μM) and inhibitory activities with IC₅₀ = 23.8 nM in Ba/F3-LMNA-NTRK1^WT cells.^[1].
TRK-IN-33 (0.1-10 μM, 24 h) displays favorable dose-dependent degradation on TRKA G667C mutant protein in Ba/F3-LMNA-NTRK1^G667C cells^[1].
TRK-IN-33 (1 μM) exhibits superior pharmacokinetic properties in CD-1 mice, SD rats, or humans microsomes with T_1/2 = 24.8, 53.8 and 57.1min; C_Lint = 0.0683, 0.0599 and 0.0230 mL/min/mg, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Ba/F3-LMNA-NTRK1^G667C cells
Concentration:

0.1, 1 and 10 μM
Incubation Time:

24 h
Result:

Exhibited > 90% maximal degradation, potentially overcoming on-target resistance in TRKA G667C resistant mutation.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞	CL	MRT_0-t	MRT_0-∞	F
Mice^[1]	1 mg/kg	i.v.	0.249 h	0.083 h	590 ng/mL	231 ng·h/mL	232 ng·h/mL	442 mL/h/kg	0.268 h	0.275 h	/
Mice^[1]	10 mg/kg	p.o.	0.437 h	0.500 h	754 ng/mL	930 ng·h/mL	932 ng·h/mL	4313 mL/h/kg	0.903 h	0.911 h	40.2 %

In Vivo

TRK-IN-33 (compound 20) (30 or 50 mg.kg, i.p., twice daily for 28 consecutive days) overcomes TRK resistance driven by the G667C mutation with good tolerability and safety profile in the Ba/F3-LMNA-NTRK1^G667C mice xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Ba/F3-LMNA-NTRK1 sup>G667C cells (3 × 10⁶) induced-female BALB/c nude mice (18-22 g, 4 weeks old)^[1]
Dosage:

30 or 50 mg/kg
Administration:

i.p., twice daily for 28 consecutive days
Result:

Significantly inhibited tumor growth in a dose-dependent manner, with inhibition rates of 71.65 and 80.38% at 30 and 50 mg/kg, respectively.
Observed no statistically significant changes in body weight.
Revealed no apparent damage in major organs, including the heart, liver, spleen, lung, and kidney.
Revealed g a significant reduction of TRK fluorescence intensity.
Suppressed tumor cell proliferation and enhanced apoptosis in tumor tissues.

Chemical Information

Molecular Weight 472.90
Formula C₂₂H₂₂ClFN₆O₃
SMILES

FC1=C(NC(C2=NN(C(C)C)C(N)=C2C(N)=O)=O)C=C(NC(CC3=CC=C(Cl)C=C3)=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Song J, et al. Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance. J Med Chem. 2025 Dec 25;68(24):26383-26404. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock